HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Del Labs results

This article was originally published in The Rose Sheet

Executive Summary

Sally Hansen retail sales increased 14% in 2002, company reports, citing ACNielsen data. Brand boosted Del Labs consolidated sales 15.1% to $350.7 mil. for the year, while net earnings soared 99.1% to $19.5 mil., including an after-tax gain of $1.5 mil., company announces Feb. 27. Sally Hansen Healing Beauty color cosmetics line will be supported with national print ad campaign breaking in April carrying the tagline, "Future of beauty," firm says. Line will be promoted with "a couple million" samples, in-store demonstrations, FSIs and coupons. Healing Beauty, which bowed in mass market stores in January, is projected to generate $100 mil. in first-year sales (1"The Rose Sheet" Dec. 2, 2002, p. 3)...

You may also be interested in...



Sally Hansen Color Cosmetics Bring Healing Positioning To Category

Del Labs is making a full-scale push into the color cosmetics category in January with the launch of Sally Hansen Healing Beauty, a makeup line with a "good-for-you" positioning, Exec VP-Marketing William McMenemy said

DevaCurl Faces Multiple Class Actions As Latest Brand Linked To Hair Loss

The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

UsernamePublicRestriction

Register

RS011007

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel